Umer Raffat, Evercore ISI senior analyst, discusses the volatility in Merck as shares plummet after withdrawing drug application for its lung cancer drug in Europe.
Administration officials say he was not interested in other topics | Email not displaying correctly? View it in your browser. Subscribe to TIME magazine WHAT TO KNOW NOW LISTEN ...
Comentarios
Publicar un comentario